Bio-Rad Laboratories, Inc. (BIO)

NYSE: BIO · USD

$384

+3.20 (+0.8%)· Recorded snapshot

英語版にフォールバックJA

翻訳中のため英語版を表示しています

このレポートはまだ翻訳されていません。翻訳キューが追いついたら数分後に更新してください。

StockMarketAgent Research · Analyzed 2026-10-14

Our latest published analysis: BIO rated Sell

Bio-Rad Laboratories, Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$165 / share

Potential value

$195 / share

Upside to FV

-54.5%

from $384

Moat

6/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$9.7B
Revenue (ttm)	2.6B
Net income (ttm)	222.4M
EPS (ttm)	$8.26
Shares out	26.7M
P/E (trailing)	46.5x
P/E (forward)	41.3x
Volume	190,866
Beta	1.07

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 2.6B
Net income (ttm): 222.4M
EPS (ttm): $8.26
P/E (trailing): 46.5x
P/E (forward): 41.3x
Market cap: $9.7B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$2.92B	$2.80B	$2.67B	$2.57B	$2.58B	-3.0%
Gross profit	$1.64B	$1.57B	$1.43B	$1.38B	$1.34B	-4.9%
Operating income	$500.3M	$482.6M	$337.8M	$269.0M	$47.2M	-44.6%
Net income	$4.25B	$-3.63B	$-637.3M	$-1.84B	$759.9M	-35.0%
EPS (diluted)	$140.83	$-39.59	$-21.82	$-65.36	$27.85	-33.3%
EBITDA	$5.59B	$-4.53B	$-654.8M	$-2.14B	$1.21B	-31.8%
R&D	$260.6M	$256.9M	$247.4M	$295.9M	$275.6M	+1.4%
SG&A	$877.1M	$827.8M	$841.7M	$814.0M	$844.3M	-0.9%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	5T	39.4x	10.8x	101.6%	+6.1%	+28.5%	売り
ABNB	Airbnb, Inc.	97.8B	37.5x	7.4x	16.8%	+24.4%	+28.5%	売り
ADBE	Adobe Inc.	97.1B	13.9x	3.7x	57.2%	+11.5%	-30.7%	強い買い
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	売り
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	縮小
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	縮小

Base and Bull scenarios

Base55%

Price target

$164.82

-54.5% from spot

In the base case, Clinical Diagnostics quality controls and blood typing generate steady recurring cash flows, offsetting near-term instrument weakness in Life Science. Operating margins expand modestly in FY2027 and normalize through FY2030 as operating expense rationalization takes hold. Consolidated revenue growth inflects higher after FY2027. Intrinsic valuation yields a central Fair value of $164.82 per share.

Consolidated revenue growth transitions from -0.53% in FY2026 to 2.13% in FY2027 and 4.0%-4.5% long-term.
Non-GAAP operating margin normalizes from 11.0% in FY2026 to 14.5% by FY2030.
Terminal price-to-earnings multiple applied on forward earnings consistent with historical company averages.

Bull20%

Price target

$195.36

-46.1% from spot

In the bull case, biopharma research funding experiences a rapid recovery in FY2027, unlocking pent-up demand for Life Science instruments. Catalog assay migration onto Stilla ddPCR platforms drives strong consumable growth, while facility restructuring delivers faster-than-expected margin leverage. Operating margins expand beyond guidance toward upper-teen levels, supporting strong earnings growth.

Life Science revenue rebounds >5% annually led by Stilla ddPCR platform adoption.
Operating margins expand rapidly through FY2030 driven by aggressive operating expense restructuring and manufacturing efficiency.
Valuation multiple holds at an elevated terminal price-to-earnings multiple reflecting sustained market leadership.

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($164.82). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	2.0%	2.3%	2.5%	2.8%	3.0%
8.5%	$177	$180	$184	$188	$192
9.0%	$168	$171	$174	$177	$181
9.5%	$160	$162	$165	$168	$171
10.0%	$153	$155	$157	$159	$162
10.5%	$146	$148	$150	$152	$154

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E41.3

P25 n/aP50 n/aP75 n/a

Trailing P/E46.1

P25 n/aP50 n/aP75 n/a

ROE3.1

P25 n/aP50 n/aP75 n/a

ROIC2.5

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All BIO indicators

Market & fundamental data

Available fields

269

Groups with data

Currency

USD

Showing 269 of 269 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000012208
Company name	Bio-Rad Laboratories, Inc.
Country	United States
Country code	US
CUSIP number	090572207
Earnings date	2026-11-04
Earnings time	amc
Employees	7,450
Employees change	-250
Employees growth	-3.25%
Enterprise value	$10B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1952
Industry	Medical Devices
Is primary listing	Yes
Is SPAC	No
ISIN number	US0905722072
Last 10-K release date	2026-02-13
Last earnings date	2026-08-04
Last refreshed	2026-10-28
Last stock split date	2002-03-08
Last stock split type	Forward
Market cap	$10.3B
Market cap category	Large-Cap
Next earnings date	2026-11-04
Options	Yes
Price	$384.18
Price currency	USD
Sector	Healthcare
SIC code	3826
Stock price date	2026-10-28
Symbol	BIO
U.S. state	California
Website	https://www.bio-rad.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	41.4x
Average P/E ratio (10Y)	65.26x
Earnings yield	2.15%
EV/Earnings	44.64x
EV/EBIT	36.46x
EV/EBITDA	22.51x
EV/FCF	28.12x
EV/Sales	3.83x
FCF / EV yield	3.56%
FCF yield	3.47%
Forward EV/Sales	3.78x
Forward P/E	41.91x
Forward P/S	3.87x
Graham number	223.23868
Graham upside	-41.35%
Industry forward P/E	19.81x
Industry P/E	39.28x
Lynch fair value	$41.28
Lynch upside	-89.16%
P/(FCF - SBC) ratio	34.76x
P/(OCF - SBC) ratio	23.54x
P/B ratio	1.42x
P/E ratio	46.54x
P/FCF ratio	28.82x
P/OCF ratio	20.66x
P/S ratio	3.93x
Price / tangible book value	1.58x
Price/EBITDA ratio	23.08x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	10.52%
EBITDA margin	17.03%
Effective tax rate	36.53%
FCF margin	13.64%
Gross margin	52.04%
Operating margin	10.52%
Pretax margin	13.53%
Profit margin	8.59%
Profit per employee	$29,852
Profitable quarters	1
Profitable years	1
Revenue per employee	$347,557
ROA	1.66%
ROA (5Y)	1.87%
ROCE	2.93%
ROE	3.11%
ROE (5Y)	-3.05%
ROIC	2.54%
ROIC (5Y)	3.87%
SBC / revenue	2.33%
Tax / revenue	4.94%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-28.17%
EPS growth (Q)	18.68%
EPS growth 10Y	9.61%
EPS growth 5Y	-42.73%
EPS growth quarters	1
EPS growth years	1
FCF growth	-4.83%
FCF growth (Q)	-5.79%
FCF growth (QoQ)	-14.6%
FCF growth 3Y	31.84%
FCF growth 5Y	-9.65%
Gross profit growth	-1.12%
Gross profit growth (Q)	0.14%
Gross profit growth 3Y	-3.42%
Gross profit growth 5Y	-3.73%
Net income growth	-30.33%
Net income growth (Q)	16.87%
Net income growth 5Y	-44.02%
Net income growth quarters	1
Net income growth years	1
OCF growth	-7.79%
OCF growth (Q)	-15.28%
OCF growth (QoQ)	-8.7%
OCF growth 10Y	10.12%
OCF growth 3Y	19.76%
OCF growth 5Y	-6.48%
Operating income growth	14.36%
Operating income growth (Q)	-5.7%
Operating income growth 3Y	-9.66%
Operating income growth 5Y	-11.79%
Revenue growth	1.37%
Revenue growth (Q)	-0.09%
Revenue growth (QoQ)	9.95%
Revenue growth 10Y	2.47%
Revenue growth 3Y	-2.21%
Revenue growth 5Y	-2.1%
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-139.5M
Depreciation and amortization	$168.7M
EBIT	$272.3M
EBITDA	$441M
EPS	$8.26
FCF per share	$13.21
Financing cash flow	$-120.8M
Free cash flow	$353.1M
Free cash flow minus SBC	$292.8M
Gross profit	$1.3B
Income taxes	$128M
Investing cash flow	$-237.1M
Net borrowing	$-500,000
Net cash flow	$147.1M
Net income	$222.4M
Operating cash flow minus SBC	$432.3M
Operating income	$272.3M
Revenue	$2.6B
Stock-based compensation	$60.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	3.19
Book value per share	$268.30
Debt / EBITDA	2.69
Debt / equity	0.19
Debt / FCF	3.88
Goodwill	$574.3M
Interest coverage	5.58
Long-term assets	$7.2B
Long-term liabilities	$2.1B
Net cash (debt)	$248.1M
Net cash / market cap	2.44%
Net debt / EBITDA	-0.56
Net debt / equity	-0.03
Net debt / FCF	-0.7
Piotroski F-Score	5
Property, plant and equipment	$671.9M
Shareholders' equity	$7.2B
Tangible book value	$6.4B
Tangible book value per share	$240.84
Total assets	$10.3B
Total cash	$1.6B
Total debt	$1.4B
Total liabilities	$3.1B
WACC	9.19%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.25
Current assets	$3B
Current liabilities	$961.3M
Current ratio	3.14
Inventory turnover	1.57
Net working capital	$875M
Quick ratio	2.15
Working capital	$2.1B
Working capital turnover	1.2

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	3.11%
Dividend yield	0%
Shareholder yield	3.11%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	143.5%
10Y return CAGR	9.31%
10Y total return	143.5%
150-day SMA	$322.21
15Y price change	280.96%
15Y return CAGR	9.33%
15Y total return	280.96%
1D price change	0.84%
1M price change	0.69%
1M total return	0.69%
1W price change	8.22%
1W total return	8.22%
1Y price change	14.14%
1Y return CAGR	14.15%
1Y total return	14.14%
20-day SMA	$365.76
200-day SMA	$312.82
20Y price change	416.05%
20Y return CAGR	8.55%
20Y total return	416.05%
3M price change	21.25%
3M total return	21.25%
3Y price change	41.73%
3Y return CAGR	12.32%
3Y total return	41.73%
50-day SMA	$374.46
50-day SMA vs 200-day SMA	50over200
52-week high	$396.23
52-week high date	2026-08-27
52-week low	$236.73
52-week low date	2026-05-13
5Y price change	-49.83%
5Y return CAGR	-12.89%
5Y total return	-49.83%
6M price change	33.53%
6M total return	33.53%
All-time high	$832.70
All-time high date	2021-09-02
All-time low	$0.85
All-time low date	1982-08-19
Average true range (ATR)	$11.42
Average volume	216.5K
Beta (1Y)	1.13
Beta (2Y)	0.81
Beta (5Y)	1.07
Change from 52-week high	-3.04%
Change from 52-week low	62.29%
Change from all-time high	-53.93%
Change from all-time low	44,934.92%
Change from open	-0.21%
Day's gap	1.05%
Dollar volume	$73.3M
High price	$385.84
Low price	$380.91
Monthly RSI	60.07
Open price	$385.00
Position in 52-week range	66.33%
Premarket change	-0.03%
Premarket close	$380.99
Premarket price	$380.88
Previous close	$380.99
Price vs 150-day SMA	19.06%
Price vs 20-day SMA	4.88%
Price vs 200-day SMA	22.63%
Price vs 50-day SMA	2.45%
Relative volume	0.88
RSI	61.91
Sharpe ratio	0.44
Sharpe ratio (3Y)	0.29
Sharpe ratio (5Y)	-0.27
Sortino ratio	0.8
Sortino ratio (3Y)	0.6
Sortino ratio (5Y)	-0.23
Volume	190.9K
Weekly RSI	63.68
YTD price change	26.62%
YTD total return	26.62%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	21.4M
Float percentage	79.85%
Shares change (QoQ)	-0.53%
Shares change (YoY)	-3.11%
Shares held by insiders	4.79%
Shares held by institutions	72.87%
Shares outstanding	26.7M
Short % of float	5.54%
Short % of shares	4.42%
Short ratio	4.4 days

Deeper analysis on BIO

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this BIO report

What is the latest published BIO stock rating?

Bio-Rad Laboratories, Inc. is shown with Sell in the latest published report, analyzed 2026-10-14. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full BIO analysis?

The full latest published report, analyzed 2026-10-14, lives at /stocks/BIO/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for BIO?

The latest published report analyzed 2026-10-14 gives BIO a fair value of USD 165 and a potential value of USD 195. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the BIO page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-10-14). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

SellBIO · Fair value $165-54.5%

Read full analysis →

Bio-Rad Laboratories, Inc. (BIO)

Our latest published analysis: BIO rated Sell

Price

Financial snapshot

Fair-value bridge

Latest news · BIO

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All BIO indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on BIO

Frequently asked questions

レーティング履歴

Category	Score	Reading
Valuation	1.5
Management	6.5
Balance Sheet	8.5
Profitability	3.5
Revenue Growth	2.5
Risk Assessment	8.0
Competitive Moat	6.0
Earnings Quality	5.5
Capital Efficiency	2.5